February 5, 2018
January 26, 2018
September 5, 2017
InVivo Therapeutics Announces Closing of Public Offering of Common Stock November 22, 2019
InVivo Therapeutics Announces Pricing of Public Offering of Common Stock November 21, 2019
InVivo Therapeutics Announces Proposed Public Offering of Common Stock November 18, 2019
“As evidenced by the passing of the 21st Century Cures Act, regulators and policy makers have recently highlighted the benefits and utility of Real-World Evidence (RWE) as it pertains to the Food and Drug Administration (FDA) regulatory decision-making for medical devices. RWE is derived from Real World Data (RWD) collected outside of a traditional clinical trial and includes sources such as patient registries. InVivo is committed to providing regulatory agencies with a comprehensive benchmark comparator dataset using RWE to help support the assessment of the safety and probable benefit of its Neuro-Spinal Scaffold™. ” For full text, click here.
Mark Perrin, CEO and Chairman, 5/30/2017